HIM
SWTX

Hillsdale Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Hillsdale Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-170
Closed -$5.45K – 678
2024
Q3 		$5.45K Buy
170
+40
+31% +$1.49K ﹤0.01% 571
2024
Q2 		$4.9K Buy
+130
New +$5.47K ﹤0.01% 564

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hillsdale Investment Management's SWTX Position: Q4 2024 in Review

Hillsdale Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 170 shares — an estimated $5.45K sold.

Hillsdale Investment Management first reported a position in SWTX in Q2 2024 and held it in 2 quarters. The position peaked at $5.45K in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Hillsdale Investment Management reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 170 SpringWorks Therapeutics shares in Q4 2024, an estimated $5.45K.
  • Hillsdale Investment Management first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 2 quarters.
  • Hillsdale Investment Management's SpringWorks Therapeutics position peaked at $5.45K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Hillsdale Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.